• LAST PRICE
    26.8800
  • TODAY'S CHANGE (%)
    Trending Down-0.0100 (-0.0372%)
  • Bid / Lots
    26.8700/ 2
  • Ask / Lots
    26.9100/ 1
  • Open / Previous Close
    26.8800 / 26.8900
  • Day Range
    Low 26.8700
    High 26.9000
  • 52 Week Range
    Low 7.6700
    High 27.0250
  • Volume
    280,737
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 26.89
TimeVolumeMYOV
09:32 ET551626.89
09:33 ET70026.89
09:35 ET50026.89
09:37 ET1191426.89
09:39 ET30026.89
09:42 ET310026.885
09:44 ET106126.89
09:46 ET82426.89
09:48 ET72226.89
09:50 ET187226.88
09:51 ET180026.89
09:55 ET60026.885
09:57 ET20026.89
10:00 ET50026.885
10:02 ET318726.88
10:04 ET30026.885
10:08 ET20026.885
10:09 ET20026.885
10:11 ET20026.89
10:13 ET72126.89
10:15 ET59426.89
10:18 ET133126.89
10:20 ET40026.885
10:22 ET10026.89
10:24 ET30026.89
10:26 ET10026.885
10:27 ET50026.89
10:29 ET10026.89
10:31 ET132626.89
10:33 ET333226.895
10:36 ET20026.9
10:38 ET30026.9
10:40 ET119126.895
10:42 ET32326.9
10:44 ET40026.9
10:45 ET42626.9
10:49 ET40026.89
10:51 ET90026.9
10:54 ET59226.9
10:56 ET108326.9
10:58 ET10026.9
11:00 ET20026.9
11:02 ET152526.9
11:05 ET10026.9
11:07 ET20026.895
11:09 ET50026.9
11:12 ET40026.9
11:14 ET37426.9
11:16 ET70526.895
11:20 ET10026.895
11:23 ET30026.9
11:39 ET49926.9
11:41 ET134326.9
11:45 ET10626.9
11:48 ET30026.9
11:50 ET20026.9
11:52 ET30826.9
11:59 ET10026.89
12:12 ET10026.9
12:14 ET10026.8999
12:19 ET30026.9
12:21 ET10026.9
12:32 ET10026.89
12:33 ET20026.9
12:35 ET10026.9
12:39 ET40026.895
12:44 ET10026.89
12:46 ET90026.9
12:51 ET110026.9
12:53 ET10026.895
12:55 ET30026.9
01:00 ET62826.9
01:02 ET10026.9
01:04 ET40026.89
01:06 ET10026.89
01:08 ET15026.896
01:11 ET20026.9
01:13 ET10026.9
01:15 ET1177726.895
01:18 ET30026.89
01:20 ET20026.895
01:22 ET20026.9
01:24 ET10026.89
01:26 ET65026.8928
01:29 ET60026.89
01:33 ET10026.9
01:42 ET10026.89
01:44 ET10026.89
01:45 ET90026.89
01:49 ET10026.89
01:51 ET10026.9
01:54 ET25026.9
02:00 ET60026.89
02:02 ET30026.89
02:05 ET10026.9
02:07 ET10026.9
02:09 ET30026.9
02:16 ET10026.895
02:23 ET30026.89
02:27 ET25826.895
02:32 ET30026.895
02:34 ET100026.89
02:41 ET10026.895
02:43 ET166926.895
02:45 ET30026.89
02:48 ET20026.89
02:52 ET10026.89
02:56 ET20026.895
02:57 ET97926.895
03:01 ET138526.895
03:03 ET10026.9
03:08 ET1471226.895
03:10 ET561626.895
03:12 ET60026.895
03:14 ET10526.895
03:15 ET640026.9
03:17 ET20026.9
03:19 ET10026.9
03:21 ET112026.89
03:24 ET38926.9
03:28 ET160026.895
03:30 ET68926.895
03:32 ET70326.89
03:33 ET45026.89
03:35 ET53326.89
03:37 ET83026.895
03:39 ET10026.9
03:42 ET191026.89
03:44 ET90026.895
03:46 ET147526.89
03:48 ET20026.895
03:50 ET36826.895
03:51 ET1164226.895
03:53 ET150026.89
03:55 ET1917626.88
03:57 ET506326.88
04:00 ET8168226.88
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesMYOV
Myovant Sciences Ltd
2.6B
-14.0x
---
United StatesFGEN
FibroGen Inc
2.3B
-6.3x
---
United StatesPRTA
Prothena Corporation PLC
2.8B
-17.3x
---
United StatesINSM
Insmed Inc
2.9B
-5.9x
---
United StatesBPMC
Blueprint Medicines Corp
2.9B
-3.8x
---
United StatesCVAC
CureVac NV
2.2B
-15.6x
---
As of 2023-02-03

Company Information

Myovant Sciences Ltd is a biopharmaceutical company. The Company is focused on redefining care for women and for men through science, medicines and transformative advocacy. The Company’s two products include ORGOVYX (relugolix 120 mg), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer; and MYFEMBREE, a once-daily oral treatment for the management of heavy menstrual bleeding associated with uterine fibroids. The Company, through its subsidiary, Myovant Sciences GmbH develops supplemental New Drug Application for once-daily MYFEMBREE for the management of moderate to severe pain associated with endometriosis and being assessed for contraceptive efficacy in women ages 18-35 years who are at risk for pregnancy. It develops Relugolix for the treatment of men with advanced prostate cancer. The Company is also developing MVT-602, which has completed a Phase IIa study for the treatment of female infertility.

Contact Information

Headquarters
Ste 1 3rd Fl, 11/12 St. James's SquareLONDON, United Kingdom SW1Y 4LB
Phone
207-400-3351
Fax
---

Executives

Non-Executive Chairman of the Board
Myrtle Potter
Principal Executive Officer, Director
David Marek
Chief Financial and Business Officer, Principal Financial and Accounting Officer
Uneek Mehra
General Counsel, Corporate Secretary and Chief Legal and Administrative Officer and Corporate Secretary of Myovant Sciences, Inc.
Matthew Lang
Chief Medical Officer
Juan Camilo Arjona Ferreira

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$2.6B
Revenue (TTM)
$379.1M
Shares Outstanding
97.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.18
EPS
$-1.92
Book Value
$-4.99
P/E Ratio
-14.0x
Price/Sales (TTM)
6.9
Price/Cash Flow (TTM)
---
Operating Margin
-38.75%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.